Aura Biosciences, Inc. AURA Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $6.63M-29.7% | $9.43M+9.8% | $8.59M+361% | $1.86M+14,223% | ||
| $90.3M+23.2% | $73.3M+12.4% | $65.23M+54.4% | $42.24M+67.9% | ||
| $22.49M-1.4% | $22.81M+15.5% | $19.76M+9.4% | $18.06M+79.0% | ||
| $112.79M+17.4% | $96.11M+13.1% | $84.99M+41.0% | $60.3M+71.0% | ||
| -$112.79M-17.4% | -$96.11M-13.1% | -$84.99M-41.0% | -$60.3M-71.0% | ||
| $6.71M-27.9% | $9.31M+6.7% | $8.72M+469% | $1.53M+153,300% | ||
| -$106.08M-22.2% | -$86.81M-13.8% | -$76.27M-29.8% | -$58.76M— | ||
| $107K-5.3% | $113K-17.5% | $137K— | $0— | ||
| -$106.19M-22.2% | -$86.92M-13.8% | -$76.41M-30.0% | -$58.76M-66.7% | ||
| -$1.79-2.3% | -$1.75+8.9% | -$1.92+2.0% | -$1.96— | ||
| -$1.79-2.3% | -$1.75+8.9% | -$1.92+2.0% | -$1.96— | ||
| 234.4M+18.2% | 198.3M+29.2% | 153.4M+30.4% | 117.7M+1,727% | ||
| 234.4M+18.2% | 198.3M+29.2% | 153.4M+30.4% | 117.7M— | ||
| -$106.56M-22.2% | -$87.2M-15.0% | -$75.8M-28.8% | -$58.84M-56.6% | ||
| $6.63M-29.7% | $9.43M+9.8% | $8.59M+361% | $1.86M+14,223% | ||
| -$179K+33.9% | -$271K-144% | $611K— | —— | ||
| -$186K-3,620% | -$5K— | —— | —— | ||
| $76K+163% | -$120K-57.9% | -$76K— | —— | ||
| -$112.79M-17.4% | -$96.11M-13.1% | -$84.99M-41.0% | -$60.3M-71.0% | ||
| -$111.63M-17.6% | -$94.92M-13.5% | -$83.64M-41.5% | -$59.12M-71.7% | ||
| -$111.63M-17.6% | -$94.92M-13.5% | -$83.64M-41.5% | -$59.12M-71.7% | ||
| -$112.79M-17.4% | -$96.11M-13.1% | -$84.99M-41.0% | -$60.3M-71.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aura Biosciences, Inc. profitable?
- Aura Biosciences, Inc. is not currently profitable: it reported a net loss of $112.4M over the trailing twelve months.
- What is Aura Biosciences, Inc.'s earnings per share?
- Aura Biosciences, Inc.'s diluted EPS over the trailing twelve months is $-1.74.
- Where does Aura Biosciences, Inc.'s income statement data come from?
- Every line is extracted from Aura Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.